Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT20231119060108N1
IRCT20231119060108N1RecruitingPhase 2

Safety and Efficacy of Rituximab in patients with juvenile dermatomyositis (JDM) who were admitted at Mofid children hospital

Shahid Beheshti University of Medical Sciences0 sites7 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
7
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to 16 years (—)
Sex
All

Inclusion Criteria

  • •Patient under 16 years old
  • •Patients with the diagnosis of dermatomyositis, which is confirmed based on the diagnosis criteria

Exclusion Criteria

  • •Presence of concomitant diseases and overlap syndrome
  • •Contraindications for rituximab injection

Investigators

Similar Trials

Active, not recruiting
Not Applicable
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritis
EUCTR2006-001000-37-DERoche Pharma AG300
Active, not recruiting
Not Applicable
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.
EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
Completed
Not Applicable
Efficacy and safety of rituximab for patients with severe rheumatic diseaseChildhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren&#39s syndrome, anti-phospholipid syndrome)
JPRN-UMIN000018376Yokohama City University Hospital Department of Pediatrics20
Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating Polyneuropathy
JPRN-UMIN000035753agoya University Hospital27
Completed
Phase 2
RECIPE TrialChronic Inflammatory Demyelinating Polyneuropathy
JPRN-jRCT2041180037Iijima Masahiro25